GSK – Pharma Boss Aims For 14% Returns On Late Stage Pipeline
it had posted a strong performance in a challenging year with a return to
sales growth for the first time since 2007.
In an interview on http://www.cantos.com CEO
a reduction in the investment into treatments for pain and depression and a
restructuring of R&D.
“Now obviously I don’t like to see anybody leave the organisation or
there to be any job losses. But the reality is that we do, from time to time,
need to look at ways in which we can improve our probability of success.”
The interview and transcript are available now on http://www.cantos.com.
Cantos.com, the online financial broadcaster, features in-depth
interviews, documentaries and webcasts with senior company executives. If you
would like to contact us, please email email@example.com or phone